Editorial: Clinical Trials in Cardiovascular Medicine: 2025 — Addressing Residual Cardiovascular Risks Through Precision-Guided Approaches - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Editorial: Advancements in Cardiovascular Clinical Trials by 2025 — Tackling Remaining Cardiovascular Risks with Precision Medicine Strategies

  • By

  • Wang, Euscia Y

  • XU, KEMAN

  • Shao, Ying

  • Lu, Yifan

  • Hung, Shih yu

  • Yuan, Bo

  • Xiang, Haiyan

  • Wang, Hong

  • Yang, MD, PhD, Professor Xiaofeng

  • July 2, 2026

Share

Original Source(s)

Editorial: Clinical Trials in Cardiovascular Medicine: 2025 — Addressing Residual Cardiovascular Risks Through Precision-Guided Approaches

  • by Wang, Euscia Y, XU, KEMAN, Shao, Ying, Lu, Yifan, Hung, Shih yu, Yuan, Bo, Xiang, Haiyan, Wang, Hong, Yang, MD, PhD, Professor Xiaofeng

  • July 2, 2026

Related Content

Embedding structural and social determinants of cardiovascular health into medical education: a systematic review of pedagogical frameworks

A two-phase machine learning framework for coronary heart disease risk prediction: Integrating population ecology with individual pathophysiology

Machine learning prediction of hypertension integrating polygenic risk scores in inner Eurasian populations